Phase3 trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer LETS Biomarker study [EXTENSION OF 700016987].
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2017
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms LETS Biomarker
- 02 Aug 2016 Status changed from active, no longer recruiting to completed.
- 23 May 2014 New trial record